WallStreetZenWallStreetZen

NASDAQ: CPRX
Catalyst Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their CPRX stock forecasts and price targets.

Forecast return on equity

Is CPRX forecast to generate an efficient return?

Company
38.03%
Industry
130.14%
Market
-52.51%
CPRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CPRX forecast to generate an efficient return on assets?

Company
33.5%
Industry
47.48%
CPRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CPRX earnings per share forecast

What is CPRX's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$2.19+26.59%
Avg 2 year Forecast
$2.30+33.14%
Avg 3 year Forecast
$2.59+49.71%
CPRX's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

CPRX revenue forecast

What is CPRX's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$561.5M+0.54%
Avg 2 year Forecast
$620.7M+11.13%
Avg 3 year Forecast
$697.6M+24.91%
CPRX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CPRX earnings growth forecast

How is CPRX forecast to perform vs Biotechnology companies and vs the US market?

Company
13.43%
Industry
5.13%
Market
15.2%
CPRX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
CPRX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
CPRX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

CPRX revenue growth forecast

How is CPRX forecast to perform vs Biotechnology companies and vs the US market?

Company
7.5%
Industry
83.67%
Market
10.8%
CPRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CPRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CPRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CPRX$20.02N/AN/A
FOLD$7.97$46.33+481.34%Strong Buy
MLYS$37.29$42.60+14.24%Strong Buy
VCYT$31.83$42.00+31.95%Strong Buy
BLTE$73.00$89.00+21.92%Strong Buy
View Top Biotech Stocks

Catalyst Pharmaceuticals Stock Forecast FAQ

What is CPRX's earnings growth forecast for 2025-2027?

(NASDAQ: CPRX) Catalyst Pharmaceuticals's forecast annual earnings growth rate of 13.43% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.2%.

Catalyst Pharmaceuticals's earnings in 2025 is $208,665,000.On average, 3 Wall Street analysts forecast CPRX's earnings for 2025 to be $268,036,312, with the lowest CPRX earnings forecast at $261,916,761, and the highest CPRX earnings forecast at $271,708,042. On average, 3 Wall Street analysts forecast CPRX's earnings for 2026 to be $281,903,213, with the lowest CPRX earnings forecast at $263,140,672, and the highest CPRX earnings forecast at $302,305,795.

In 2027, CPRX is forecast to generate $316,992,716 in earnings, with the lowest earnings forecast at $316,992,716 and the highest earnings forecast at $316,992,716.

If you're new to stock investing, here's how to buy Catalyst Pharmaceuticals stock.

What is CPRX's revenue growth forecast for 2025-2027?

(NASDAQ: CPRX) Catalyst Pharmaceuticals's forecast annual revenue growth rate of 7.5% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.8%.

Catalyst Pharmaceuticals's revenue in 2025 is $558,499,000.On average, 4 Wall Street analysts forecast CPRX's revenue for 2025 to be $68,721,328,205, with the lowest CPRX revenue forecast at $68,573,235,083, and the highest CPRX revenue forecast at $68,858,406,136. On average, 4 Wall Street analysts forecast CPRX's revenue for 2026 to be $75,963,816,222, with the lowest CPRX revenue forecast at $74,536,125,090, and the highest CPRX revenue forecast at $78,048,747,077.

In 2027, CPRX is forecast to generate $85,380,335,749 in revenue, with the lowest revenue forecast at $82,239,415,259 and the highest revenue forecast at $88,207,200,907.

What is CPRX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: CPRX) forecast ROA is 33.5%, which is lower than the forecast US Biotechnology industry average of 47.48%.

What is CPRX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: CPRX) Catalyst Pharmaceuticals's current Earnings Per Share (EPS) is $1.73. On average, analysts forecast that CPRX's EPS will be $2.19 for 2025, with the lowest EPS forecast at $2.14, and the highest EPS forecast at $2.22. On average, analysts forecast that CPRX's EPS will be $2.30 for 2026, with the lowest EPS forecast at $2.15, and the highest EPS forecast at $2.47. In 2027, CPRX's EPS is forecast to hit $2.59 (min: $2.59, max: $2.59).

What is CPRX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: CPRX) forecast ROE is 38.03%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.